Phosphorylation of vitronectin by a protein kinase in human plasma. Identification of a unique phosphorylation site in the heparin-binding domain

Incubation of human plasma with 27 nM [gamma-32P]ATP in the presence of 20 mM MnCl2 results in the phosphorylation of several proteins detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. About 60% of the incorporated radioactivity is found in a 75-kDa protein containing [32P] phosphoserine. The amino-terminal amino acid sequence of the purified 75-kDa [32P]phosphoprotein is identical to that of vitronectin (also termed serum spreading factor or complement S protein). Rabbit antiserum against vitronectin precipitates greater than 90% of the 75-kDa [32P]phosphoprotein from plasma. Reverse phase chromatography of [32P]vitronectin degraded sequentially with CNBr and chymotrypsin yields one major labeled peptide. The sequence of the peptide, Ser-Arg-Arg-Pro-[32PO4]Ser-Arg-Ala-Thr, corresponds to residues 374-381 which are located in the heparin-binding fragment of vitronectin identified by Suzuki et al. [1984) J. Biol. Chem. 259, 15307-15314). Vitronectin could potentially be phosphorylated in vivo with ATP released from injured cells or secreted by platelets activated during hemostasis.     

Isolation and characterization of a partial cDNA clone for heparin cofactor II1

A human fetal liver cDNA library constructed in lambda gt11 was screened with affinity-purified rabbit antibodies raised against heparin cofactor II. One positive clone was plaque purified and the cDNA insert was completely sequenced. The clone encodes the C-terminal 167 amino acid residues of heparin cofactor II as well as the entire 3'-untranslated region of the message. Proline and leucine were identified in the P2 and P1 positions of the protease cleavage site, providing a possible explanation for the ability of heparin cofactor II to inhibit both thrombin and chymotrypsin-like proteases. The coding sequence is identical to that of the recently published human leuserpin 2 (Ragg (1986) Nucl. Acids Res. 14, 1073).     

Molecular size of dermatan sulfate oligosaccharides required to bind and activate heparin cofactor II

Heparin cofactor II (HCII) inhibits thrombin rapidly in human plasma in the presence of heparin or dermatan sulfate. To determine the minimum structure of dermatan sulfate required to activate HCII, the glycosaminoglycan was partially degraded by sequential treatment with periodate, [3H]borohydride, and sulfuric acid. Labeled oligosaccharide fragments were separated by gel filtration chromatography. Purified fragments were then applied to a column of HCII bound to concanavalin A-Sepharose, and bound oligosaccharides were eluted with a gradient of sodium chloride. Di-, tetra-, and hexasaccharide fragments did not bind to HCII, while 15% of the octasaccharides and up to 45% of larger fragments bound. Octasaccharides that bound to the HCII column had a greater negative charge than the run-through material based on anion-exchange chromatography, suggesting that they contained a greater number of sulfate groups per molecule. Fragments of dermatan sulfate containing a minimum of 12-14 sugar residues accelerated inhibition of thrombin by HCII. Fragments of this length that bound to the column of immobilized HCII had molar specific activities greater than those of the fragments that did not bind. These studies suggest that HCII is activated by dermatan sulfate fragments greater than or equal to 12 residues in length that contain a specific octasaccharide sequence required for binding to the inhibitor.     

Biosynthesis of functionally active heparin cofactor II by a human hepatoma-derived cell line

Human plasma heparin cofactor II (HCII) inhibits thrombin by rapidly forming a stable, equimolar complex in the presence of heparin or dermatan sulfate. Cultured human hepatoma-derived cells (PLC/PRF-5) secreted (approximately equal to 200 ng/ml in 3 days) a protein of MW - 72 kD that was immunoisolated and immunoblotted with anti-HCII, co-migrated on SDS-PAGE with human plasma HCII, and formed covalent complexes with thrombin (MW - 101 kD) in the presence but not absence of heparin or dermatan sulfate; these complexes co-migrated with those obtained by incubating thrombin with human plasma under the same conditions. HCII was not detectable (less than 0.13 ng/ml) in post-culture medium from cultured human umbilical vein endothelial cells or human foreskin fibroblasts.     

我国微茎类吸虫研究:ⅩⅢ.微茎类吸虫成虫结构特征排序

对我国52种微茎类吸虫的18项成虫形态学特征进行主成分分析,结果表明:卵巢位置、子宫延伸位置等7项性状对第一主成分贡献较大,提示描述器官位置的指标是重要的分类依据。52个虫种在前三个主成分上的排序图显示应将其划分成4个亚科。     

柱萤叶甲属研究（Ⅰ）鞘翅具黑色刻点的种类记述（鞘翅目：叶甲科）

本文就萤叶甲亚科中柱萤叶甲属鞘翅具黑色刻点的种类进行研究,共记述４种,我国已记录３种,其中１种为新种。     

我国微茎类吸虫的研究Ⅻ.类茎属及多黄属二新种报道：复殖目：微茎科

本文报道在湛江市附近海域海鸟体内获得的两种吸虫,经鉴定为新种,命名为巨口类茎吸虫,新种Ｍｉｃｒｏｐｈａｌｌｏｉｄｅｓ ｍａｃｒｏｓｔｏｎｒｓ ｓｐ．ｎｏｖ．,珊瑚多黄吸虫,新种Ｍｕｌｔｉｖｉｔｅｌｌｕｓ ｃｏｒａｌｉｕｓ ｓｐ．ｎｏｖ．     

以化学纯饲料饲养北京的桃蚜

应用修改后的Dadd和Mitter(1966)全纯饲料配方配制成人工饲料饲养定居在北京温室烟草上的桃蚜 Myzus persicae可完成生活史井连续饲养3代。本文描述饲料配制、饲养和取食量测定的方法。这3代初羽化无翅孤雌胎生雌蚜的平均体重分别为:440±90.7μg,264±104.9μg和312±127.9μg。用放射性同位素稀释法测定取食量的结果得悉若虫期的总取食量每蚜约为1.74μg,相当于1.16μl。     

小麦倒春寒研究现状与进展

由于全球气候变暖,近年来小麦低温灾害事件频发,尤其是拔节-孕穗期的倒春寒灾害已成为制约小麦产量和品质的重要因素之一。本文综述了小麦倒春寒灾害的发生特点(鉴定与分级、时空特征),倒春寒对小麦生理特性(叶片、茎秆、穗部、根系)和产量、质量的影响,总结了抗倒春寒小麦育种、倒春寒危害的分子生物学机制及灾害的监测预警与风险评估等方面的研究进展,并从小麦抗倒春寒遗传基础、倒春寒危害小麦评价体系和防控技术体系等方面进行了展望,以期为抗倒春寒小麦品种的遗传改良和栽培调控新措施的建立提供理论依据。